TWD 75.9
(0.0%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -781.42 Million TWD | -20.55% |
2022 | -648.18 Million TWD | 24.17% |
2021 | -854.79 Million TWD | 17.47% |
2020 | -1.03 Billion TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | -864.46 Million TWD | -10.63% |
2024 Q2 | -753.03 Million TWD | 12.89% |
2023 FY | -781.42 Million TWD | -20.55% |
2023 Q3 | -1.15 Billion TWD | 23.55% |
2023 Q2 | -1.51 Billion TWD | -236.5% |
2023 Q1 | -450 Million TWD | 33.23% |
2023 Q4 | -781.42 Million TWD | 32.5% |
2022 Q4 | -673.99 Million TWD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Allied Biotech Corporation | 178.11 Million TWD | 538.723% |
GeneFerm Biotechnology Co., Ltd. | 31.92 Million TWD | 2547.604% |
Easywell Biomedicals, Inc. | 123.43 Million TWD | 733.053% |
TTY Biopharm Company Limited | -705.97 Million TWD | -10.687% |
Synmosa Biopharma Corporation | 1.52 Billion TWD | 151.365% |
Orient EuroPharma Co., Ltd. | 3.1 Billion TWD | 125.156% |
Center Laboratories, Inc. | 3.91 Billion TWD | 119.939% |
Tien Liang BioTech Co., Ltd. | -57.55 Million TWD | -1257.673% |
Orient Pharma Co., Ltd. | 633.6 Million TWD | 223.329% |
InnoPharmax Inc. | -17.85 Million TWD | -4275.753% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | -926.77 Million TWD | 15.684% |
Excelsior Biopharma Inc. | -212.51 Million TWD | -267.706% |
DV Biomed Co., Ltd. | 160.7 Million TWD | 586.261% |
Handa Pharmaceuticals, Inc. | -653.8 Million TWD | -19.519% |
UniPharma Co., Ltd. | -68.36 Million TWD | -1042.981% |
Anxo Pharmaceutical Co., Ltd. | 492.4 Million TWD | 258.695% |
Alar Pharmaceuticals Inc. | -738.05 Million TWD | -5.876% |
Winston Medical Supply Co., Ltd. | -191.81 Million TWD | -307.394% |
Mercury Biopharmaceutical Corporation | -1.94 Million TWD | -40075.938% |
Bioray Biotech Co., Ltd | -27.23 Million TWD | -2769.499% |
TSH Biopharm Corporation Limited | -568.74 Million TWD | -37.395% |